Navigation Links
BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
Date:8/14/2012

BOTHELL, Wash., Aug. 14, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record results for the second quarter ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Summary of Q2 2012 Achievements

  • The Company recorded its eighth sequential record revenue quarter, with revenue surpassing $1 million for the first time.
  • The Company commenced deliveries to its new contract manufacturing customer.
  • The Company completed the expansion of its corporate office and operations workspace and also the build-out of its second current Good Manufacturing Practice (cGMP) clean room suite.
  • To manage growing demand and projections, the Company added team members to its production team and both direct and indirect sales professionals in the period.
  • Mike Rice, Chief Executive Officer, commented: "Sales momentum continued to accelerate as we made significant investments in our infrastructure during the quarter that will position us for future growth, profitability and positive cash flows. Revenue in all of our channels was up over the same quarter last year, especially in the drug discovery and regenerative medicine segments. We also drove significant growth in our distribution channel with growing adoption of our flagship biopreservation media products. Overall, we are pleased that we are now well-positioned to capitalize on what could be substantial growth as some of our customers' regenerative medicine therapies are approved in the future."

    Second Quarter Financial ResultsTotal revenue for the second quarter of 2012 was $1.1 million, compared to $623,000 in the same period of 2011. The increase of 76% from 2011 to 2012 was due primarily to higher sales to customers in the drug discovery and regenerative medicine market segments, which were both up significantly over 2011, and the commencement of deliveries to the new contract manufacturing customer during the second quarter. Sales to direct customers in the second quarter of 2012 increased 22% compared to the second quarter of 2011 and sales to distributors increased 79% compared to the second quarter of 2011.

    Gross margin in the second quarter of 2012 was 41.5% compared to 53.6% in the second quarter of 2011. Gross margin was impacted this quarter by a combination of an increase in personnel costs included in cost of goods sold related to the ramp up of the production operation to facilitate the expected significant demand ramp from the contract manufacturing customer and by lower overall margin on contract manufacturing revenue. In addition, the Company incurred some one-time costs in the 2012 second quarter related to the facility expansion that was completed in early July. Total operating expenses in the second quarter of 2012 were $762,000, compared to $594,000 in the second quarter of 2011. The primary driver for the increase in expenses was due to higher personnel costs in 2012 as the Company continues to strategically add to its sales and marketing team. This was offset somewhat by a reduction in consulting expenses due to the termination of a consulting agreement in the third quarter of 2011.

    Other income/expense is primarily related to interest expense on the Company's notes payable.

    For the second quarter of 2012, the Company reported a net loss of $499,000, or $(0.01) per share, compared with a net loss of $437,000, or $(0.01) per share, for the second quarter of 2011. Loss from operations in the second quarter of 2012 was $307,000, compared to the $260,000 loss from operations in the second quarter of 2011.

    The Company ended the second quarter with $155,000 in cash. During the six months ended June 30, 2012, the Company reported cash provided by operations of $686,000. Included in this amount was an increase of $785,000 in deferred rent, which represents the amount the Company's landlord paid for certain tenant improvements related to the facility expansion. Excluding the increase in deferred rent, the Company used $99,000 in cash during the six months ended June 30, 2012, compared with $544,000 during the same period in 2011. The Company also recorded cash used in investing activities of $1.0 million, resulting primarily from purchases of property and equipment related. This is compared to purchases of equipment of $43,000 during the same period in 2011. Finally, during the six months ended June 30, 2012, the Company increased the total amount borrowed from investors by $475,000 compared to an increase of $620,000 during the same period in 2012. Of this amount, $300,000 was received in the second quarter of 2012.

    Outlook for 2012Management reiterates its prior revenue guidance of $4.1 million, with significant sales to its contract-manufacturing customers. The Company also expects steady increases in revenue from existing and new direct customers, specifically in the regenerative medicine market segment, and continued growth through the Company's distribution network.

    The Company expects a rebound in gross margin from the second quarter, but expects gross margin to continue to be somewhat lower than 2011 as shipments to the contract manufacturing customer stabilize during the rest of 2012, with lower overall gross margin resulting from contract manufacturing revenue. Management also expects increased operating expenses associated with selling and product development activity for the remainder of 2012. 

    Finally, management continues to believe the Company will achieve positive cash flow from operations by the end of 2012.

    About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

    This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.Media Relations:Investor Relations:Len Hall

    Matt ClawsonAllen & Caron Inc

    Allen & Caron Inc(949) 474-4300

    (949) 474-4300len@allencaron.com

    matt@allencaron.com BioLife Solutions, Inc. 

    Statement of OperationsThree MonthsEnded June 30,Six MonthsEnded June 30,2012201120122011RevenueProduct sales

    $

    1,092,409$

    617,848$

    1,923,289$

    1,223,647Licensing revenue5,0005,00010,00010,000Total revenue1,097,409622,8481,933,2891,233,647Cost of product sales641,748288,915987,877657,515Gross profit455,661333,933945,412576,132Operating expensesResearch and development126,627133,390243,148292,183Sales and marketing160,65859,132234,039142,440General and administrative475,006401,423954,119855,798Total operating expenses762,291593,9451,431,3061,290,421Operating loss(306,630)(260,012)(485,894)(714,289)Other income (expenses)Other income 5,981294,25323Interest expense(183,543)(165,239)(362,320)(325,781)Loss on disposal of property and equipment––––(63)––Amortization of deferred financing costs(14,701)(11,430)(41,746)(26,754)Total other income (expenses)(192,263)(176,667)(309,876)(352,512)Net Loss

    $

    (498,893)$

    (436,679)$

    (795,770)$

    (1,066,801)Basic and diluted net loss per

    common share

    $

    (0.01)$

    (0.01)$

    (0.01)$

    (0.02)Basic and diluted weighted average

    common shares used to calculate

    net loss per common share69,679,85469,679,85469,679,85469,679,854  Selected Balance Sheet DataJune 30,December 31,20122011Cash and cash equivalents$

    155,354$

    16,864Accounts receivable359,190547,143Inventories916,810505,956Total current assets1,508,0111,160,407Total current liabilities1,021,142579,248Promissory notes payable, related parties10,603,12710,128,127Accrued interest, related parties2,388,2812,025,961Total liabilities14,809,59512,842,503Total shareholders' equity (deficiency)(11,740,688)(11,180,486)  Selected Cash Flow DataSix Months Ended June 30, 20122011Cash provided by (used in) operating activities$

    686,007$

    (543.795)Cash used in investing activities(1,022,517)(43,271)Cash provided by financing activities475,000620,000Net increase in cash and equivalents138,49032,934
    '/>"/>

    SOURCE BioLife Solutions, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
    2. BioLife Solutions 2011 Revenue Up 33%
    3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
    4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
    5. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
    6. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
    7. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
    8. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
    9. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
    10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
    11. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
    (Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... today that the Company has concluded an agreement with ... for a 90-day period to acquire units of the ... approximately USD 3.7 million.  Concurrently with ... Tamarack under which Tamarack will seek regulatory approvals in ...
    (Date:12/2/2016)... Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy ...
    (Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
    Breaking Biology Technology:
    (Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
    (Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
    (Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
    Breaking Biology News(10 mins):